ID: MRFR/HC/7098-HCR | February 2021 | Region: Global | 90 pages
Life Science Analytics Market held a value of USD 19,165.22 Million in 2018 and is expected to register a growth of 11.91% between 2019 and 2025.
Life science analytics helps in drug discovery optimization and standardization of clinical trials. Growing adoption of analytics solutions in clinical trials, rising pressure to curb the healthcare expenditure, and increasing adoption of analytics for sales & marketing applications are the factors that are expected to drive the market growth. Moreover, the rising need for improved data standardization, increasing prevalence of chronic diseases, the need for improved patient outcomes, and the growing adoption of big data in the life sciences industry are also expected to boost market growth.
The use of life science analytical tools in clinical research institutions is increasing, as these tools are helpful in analyzing the data for ongoing clinical trials. This is expected to increase the demand for life science analytics.
By Type of Analytics
By Deployment Model
Frequently Asked Questions (FAQ) :
The valuation of the global life science analytics market had reached USD 19,165.22 MN in 2018.
The global life science analytics market is projected to grow at approximately 11.91% CAGR during the forecast period (2019-2025).
Growing adoption of analytics solutions in clinical trials.
North America holds the largest share in the global life science analytics market, followed by Europe and the Asia Pacific, respectively.
Cerner Corporation (US), Allscripts Healthcare, LLC (US), CitiusTech Inc. (US), Inovalon (US), Health Catalyst (US), McKesson Corporation (US), Optum, Inc. (US), Saama Technologies, Inc. (US), SCIOInspire, Corp. (US), IBM (US), SAS Institute Inc. (US), IQVIA (US), and Oracle (US), are some of the major players operating in the life science analytics market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.